Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese

Research and Practice in Thrombosis and Haemostasis

Volumn 2, Issue 2, 2018, Pages 274-281

  Yokoyama, Kenji ^a   Ishizuka, Naoki ^b   Uemura, Naomi ^c   Mizokami, Yuji ^d   Hiraishi, Hideyuki ^e   Murata, Mitsuru ^f   Uchiyama, Shinichiro ^g   Teramoto, Tamio ^h   Shimada, Kazuyuki ⁱ   Yamazaki, Tsutomu ^j   Oikawa, Shinichi ^k   Sugawara, Masahiro ^l   Ando, Katsuyuki ^m   Ikeda, Yasuo ⁿ  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c National Center for Global Health and Medicine   (Japan)

^d UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^h TEIKYO UNIVERSITY   (Japan)

ⁱ Shin Oyama City Hospital   (Japan)

^j UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^k Japan Anti Tuberculosis Association   (Japan)

^l Japan Physician's Association   (Japan)

^m Kitamura Neurosurgery Clinic   (Japan)

ⁿ WASEDA UNIVERSITY   (Japan)

more..

Author keywords

aspirin; cancer; elderly; incidence; Japanese

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ARTERY THROMBOSIS; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 85060199084     PISSN: None     EISSN: 24750379     Source Type: Journal    
DOI: 10.1002/rth2.12097     Document Type: Article

References (28)

1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
2. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313–6
3. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62
5. de Gaetano G; Collaborative Group of the Primary, Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89–95
6. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304
7. Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41
8. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50
9. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41
10. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601
11. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–12
12. Chan AT, Manson JE, Feskanich D, et al. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562–72
13. Jacobs EJ, Newton CC, Gapstur SM, et al. Daily Aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012;104:1208–17
14. Nan H, Carolyn M, Hutter CM, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313:1133–42
15. Lin CC, Lai MS, Shaw WY. Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. Diabet Med. 2015;32:324–31
16. Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107:1602–7
17. McCowan C, Munro AJ, Donnan PT, et al. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49:1049–57
18. Cao Y, Nishimura R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762–9
19. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26:47–57
20. Bibbins-Domingo K; on behalf of the US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836–45
21. Berger NA, Savvides P, Koroukian SM, et al. Cancer in the elderly. Trans Am Clin Climatol Assoc. 2006;117:147–55
22. ganjoho.jp 2017. Available at: http://ganjoho.jp/reg_stat/statistics/stat/short_pred.html. Accessed September 24, 2017
23. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors. A randomized clinical trial. JAMA. 2014;312:2510–20
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
25. Li L, Geraghty OC, Mehta Z, Rothwell PM; on behalf of the Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–9
26. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47–55
27. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4
28. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85